Literature DB >> 3816925

Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions.

P J Luder, B Siffert, F Witassek, F Meister, J Bircher.   

Abstract

Plasma mebendazole levels were analysed retrospectively in patients treated for inoperable infections with Echinococcus multilocularis or granulosus. In 10 patients receiving mebendazole at 4 dose levels there was no relation between dose and plasma concentration. In 17 patients followed on the same dose for more than 18 months, the plasma levels varied with individual coefficients of variation ranging from 27 to 72%. The data reveal the limitations of single measurements of plasma mebendazole and emphasize the need for repeated monitoring. Coadministration of phenytoin and carbamazepine seemed to lower plasma levels, presumably as a result of enzyme induction. It was not possible appreciably to raise the mebendazole concentrations by inhibition of drug metabolizing enzymes with cimetidine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816925     DOI: 10.1007/bf00613522

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

Review 1.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

2.  The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole.

Authors:  M Dawson; R J Allan; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

3.  Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists.

Authors:  R G Knodell; J L Holtzman; D L Crankshaw; N M Steele; L N Stanley
Journal:  Gastroenterology       Date:  1982-01       Impact factor: 22.682

4.  Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis.

Authors:  F Witassek; R J Allan; T R Watson; W Woodtli; R Ammann; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level.

Authors:  F Witassek; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man.

Authors:  F Witassek; B Burkhardt; J Eckert; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease.

Authors:  P A Braithwaite; M S Roberts; R J Allan; T R Watson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Cimetidine clearance and bioavailability in hepatic cirrhosis.

Authors:  J Sonne; H E Poulsen; M Døssing; N E Larsen; P B Andreasen
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

9.  Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients.

Authors:  E Müller; A Akovbiantz; R W Ammann; J Bircher; J Eckert; K Wissler; F Witassek; B Wüthrich
Journal:  Hepatogastroenterology       Date:  1982-12

10.  Tiotidine and cimetidine--kinetics and dynamics.

Authors:  S Kaojarern; M Feldman; C T Richardson; D C Brater
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

View more
  18 in total

Review 1.  Bone hydatid disease.

Authors:  X H Song; L W Ding; H Wen
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

2.  Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Authors:  Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; Bruno Stieger; Christiane Pauli-Magnus
Journal:  Eur J Clin Pharmacol       Date:  2009-06-27       Impact factor: 2.953

3.  In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes.

Authors:  H Jura; A Bader; M Frosch
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 5.  Diagnosis and treatment of human hydatidosis.

Authors:  H Wen; R R New; P S Craig
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 6.  Treatment of hydatid disease.

Authors:  D Anadol; U Ozçelik; N Kiper; A Göçmen
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model.

Authors:  Ren-Yuan Bai; Verena Staedtke; Teresia Wanjiku; Michelle A Rudek; Avadhut Joshi; Gary L Gallia; Gregory J Riggins
Journal:  Clin Cancer Res       Date:  2015-04-10       Impact factor: 12.531

8.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

Review 9.  Epidemiology, diagnosis, treatment, and control of trichinellosis.

Authors:  Bruno Gottstein; Edoardo Pozio; Karsten Nöckler
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

10.  Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts.

Authors:  A Bekhti; J Pirotte
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.